Menu Search
Equities

MiMedx Group Inc

MDXG:NAQ

MiMedx Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.23
  • Today's Change0.05 / 0.81%
  • Shares traded452.79k
  • 1 Year change-20.64%
  • Beta1.9782
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year MiMedx Group Inc grew revenues 20.03% from 267.84m to 321.48m. In addition the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as a percent of sales). The company reported positive net income, improving from a loss of 30.20m to a profit of 58.23m.
Gross margin83.41%
Net profit margin28.76%
Operating margin21.84%
Return on assets48.16%
Return on equity115.43%
Return on investment60.79%
More ▼

Cash flow in USDView more

In 2023, MiMedx Group Inc increased its cash reserves by 24.34%, or 16.05m. The company earned 26.78m from its operations for a Cash Flow Margin of 8.33%. In addition the company used 2.16m on investing activities and also paid 8.57m in financing cash flows.
Cash flow per share0.5986
Price/Cash flow per share9.32
Book value per share1.15
Tangible book value per share0.9305
More ▼

Balance sheet in USDView more

MiMedx Group Inc has a Debt to Total Capital ratio of 10.28%, a lower figure than the previous year's 61.18%.
Current ratio3.85
Quick ratio3.22
Total debt/total equity0.1146
Total debt/total capital0.1028
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.